The ClearBridge Global Growth Strategy seeks to provide above-market returns with market-level volatility by investing in growth companies where the portfolio managers have a differentiated view on the duration and/or magnitude of growth.
Join Portfolio Manager, Michael Testorf and Head of APAC Business Development, Matt Bushby in this video as they explore the Strategy and what it aims to achieve.
Drug development appears to be stabilizing, as improving biopharma funding and healthier demand create a more constructive backdrop for contract research organizations and life science tools companies.
Read full article